Comparative Pharmacology
Head-to-head clinical analysis: RENOQUID versus SULFAMETHOPRIM DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENOQUID versus SULFAMETHOPRIM DS.
RENOQUID vs SULFAMETHOPRIM-DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RENOQUID is a combination of sulfamethoxazole, an intermediate-acting sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. It inhibits sequential steps in bacterial folic acid synthesis: sulfamethoxazole inhibits dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, leading to bactericidal activity.
Sulfamethoprim-DS is a combination of sulfamethoxazole, a dihydropteroate synthase inhibitor, and trimethoprim, a dihydrofolate reductase inhibitor. The sequential inhibition of folate synthesis leads to bactericidal activity.
100 mg orally twice daily
Sulfamethoprim-DS (trimethoprim 160 mg-sulfamethoxazole 800 mg) orally every 12 hours for 10-14 days for uncomplicated UTI; for Pneumocystis jirovecii pneumonia: 3-5 mg/kg/day (based on TMP) orally or IV divided every 6-8 hours for 21 days.
None Documented
None Documented
Terminal elimination half-life is 2.5 hours (range 2–3 hours) in patients with normal renal function. In renal impairment (CrCl <30 mL/min), half-life may extend to 8–12 hours.
Terminal elimination half-life of sulfamethoxazole is 9-11 hours (prolonged to 20-50 hours in severe renal impairment). Clinically, this supports twice-daily dosing in normal renal function; dose adjustment required for CrCl <30 mL/min.
Renal excretion accounts for approximately 70% of elimination, with 30% excreted unchanged in urine. Biliary/fecal excretion accounts for 30%, primarily as metabolites.
Renal excretion of unchanged drug (50-70%) and metabolites (primarily N4-acetylated form, 15-30%); biliary/fecal excretion accounts for <5%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic